Lung cancer management in 2010.

Published

Journal Article (Review)

The introduction of newer therapies and approaches for management has led to a renewed excitement in the field of lung cancer. This trend has continued in 2010 with the adoption of the new staging system recommended by the International Association for the Study of Lung Cancer (IASLC). Novel targets, such as EML4-ALK, have been identified and agents targeting these abnormalities have shown promise in uncontrolled clinical trials, while other strategies, including combining targeted agents with cytotoxic chemotherapy in unselected patients, have not proven to be successful. This review summarizes important recent clinical advances that could have a significant impact on the future care of patients with lung cancer.

Full Text

Duke Authors

Cited Authors

  • Ganti, AK; Huang, CH; Klein, MA; Keefe, S; Kelley, MJ

Published Date

  • January 2011

Published In

Volume / Issue

  • 25 / 1

Start / End Page

  • 64 - 73

PubMed ID

  • 21361246

Pubmed Central ID

  • 21361246

International Standard Serial Number (ISSN)

  • 0890-9091

Language

  • eng